DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (2024)

Type 2 Diabetes | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Type 2 Diabetes | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Metformin and the sulfonylureas are the most heavily prescribed drugs in T2D and dominate the early lines of therapy prior to disease progression, which requires insulin replacement. The emergence of more-effective, safer, and/or better-tolerated therapies, such as the DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists, have provided physicians with a broad array of therapeutic options. Moreover, with a better understanding of type 2 diabetes and its complications, individualized treatment for patients is becoming more commonplace. Numerous branded agents from both established and recently emergent classes are now jostling for position in the treatment paradigm.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed T2D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed T2D patients?
  • How have Jardiance, Trulicity, and Tresiba been integrated into the treatment algorithm?
  • What percentage of T2D patients receive drug therapy within one year of diagnosis? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of T2D patients are treated with monotherapy versus combination therapy? What are the most widely used combinations?
  • What are the compliance and persistency rates for T2D therapies?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

KEY DRUGS COVERED

Afrezza, Apidra, Basaglar, Bydureon, Byetta, Farxiga, Humalog, Invokana, Januvia, Jardiance, Lantus, Levemir, Metformin, Nesina, Novolog, Onglyza, Ozempic, Toujeo, Tradjenta, Tresiba, Trulicity, Victoza

KEY ANALYSIS PROVIDED

  • Brand use across a longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
    • Treatment Algorithms Claims Data Analysis in Type 2 Diabetes [February 2019]

Already a Client? Log in to access this report.

  • Pub Date: February 2019
  • Author(s): Shreya Saxena, MBA; Gideon Heap
  • Shreya Saxena is a senior business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. She obtained an degree with specializations in Marketing and HR, and a Bachelor's degree in Pharmacy from the GGSIPU University, Delhi, India. Prior to joining DRG, she has worked as a Business Analyst at the research firm Evalueserve. Her role involved in-depth commercial, and scientific secondary research, and competitive intelligence across multiple indications (such as atrial fibrillation, ACS, VTE, heart failure and women’s health), including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, and financial assessment and benchmarking.

  • As a Principal Analyst on the Cardiovascular, Metabolic and Renal Disorders team, Gideon has a wealth of experience and expertise in pharmaceutical market analysis. In addition to creating Disease Insights covering metabolic disorders, Gideon has experience in company strategy and portfolio analysis for DRG’s Company & Drug platform. Gideon has a Masters in Biochemistry with Biological Chemistry from the University of Nottingham, and his industry experience dates back to 2009.

Purchase Report

Recent reports:
You may also be interested in: